Alzinova investor relations material
Listen to the latest call from Alzinova
Alzinova AB, a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease. The lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers
Ticker
ALZCountry
SE